#Mexico #Mexico City #Hanmi Pharmaceutical #Aditams #Gugutams

Hanmi Pharmaceutical Expands into Latin America with Aditams

In an ambitious move, Hanmi Pharmaceutical has officially launched its innovative drug, Aditams, in Mexico. This marks a significant step in the company's expansion efforts within Latin America, with the launch completed in February 2025 under a partnership with Laboratorios Silanes. This collaboration is poised to redefine treatment for patients impacted by Obstructive Prostatic Growth (OPG) and Erectile Dysfunction (ED).

The Launch and Its Significance

The introduction of Aditams represents a major milestone not just for Hanmi Pharmaceutical but also for the Mexican healthcare landscape. As a combination therapy developed for tackling two prevalent conditions faced by men, it contains tamsulosin to address OPG stemming from Benign Prostatic Hyperplasia (BPH) and tadalafil for ED. This dual-action medication is notable for being the first of its kind in the Mexican market, offering a new hope for patients who often manage these two debilitating conditions separately.

Developed using Hanmi's proprietary Poly-Cap technology, Aditams is the result of extensive research and clinical testing. This technology enables multiple active ingredients to be integrated into a single capsule, enhancing patient compliance and treatment efficiency. By providing a single solution for two related health issues, Aditams aims to improve the overall quality of life for patients.

A Strategic Partnership

Hanmi Pharmaceutical forged a partnership with Laboratorios Silanes back in October 2020, and this cooperative effort has yielded substantial results. With the launch of Aditams, Hanmi’s product lineup in Latin America now includes three successful offerings, following earlier introductions of 'Amosartan Q' and 'Amosartan Plus.'

Laboratorios Silanes has made a name in the Mexican pharmaceutical industry since its inception in 1943, known for delivering innovative healthcare solutions and rapidly growing through strategic partnerships. Their extensive distribution network positions Aditams for significant market penetration, benefiting a vast number of patients in the region. This achievement reflects the robust collaboration between the two companies and reinforces Hanmi’s commitment to growth in emerging markets.

Dr. Park's Vision

Hanmi Pharmaceutical CEO, Park Jae-hyun, emphasizes the transformative potential Aditams holds. He remarked, “As the first urological combination therapy to enter the Mexican market, Gugutams is expected to present a new treatment paradigm for local patients.” This sentiment echoes the company's strategic vision of solidifying its presence in the Latin American region while leveraging partnerships to enhance its global competitiveness.

By targeting regions like Latin America alongside its established markets in North America and Japan, Hanmi seeks to broaden its horizons and diversify its product offerings. The ongoing collaboration with Laboratorios Silanes is anticipated to serve as a critical stepping stone in this strategic endeavor.

Looking Ahead

As Aditams rolls out across Mexican pharmacies, expectations are high regarding its reception within the healthcare community and among patients. The unique benefits of addressing both OPG and ED with one capsule may significantly impact treatment protocols and patient experiences.

Hanmi Pharmaceutical aims to pave the way for more comprehensive treatment options in the urological sector while continually striving to provide innovative therapies for unmet medical needs globally. With Aditams, they are not only expanding their product offerings but also contributing positively to public health outcomes in the regions they operate in.

In conclusion, the launch of Aditams is not just a business move for Hanmi Pharmaceutical; it is a step towards enhancing the quality of life for many individuals facing these health challenges in Mexico. As they continue on this path, the anticipation grows for what further innovations and partnerships will emerge in the evolving pharmaceutical landscape.